UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 21, 2020

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

320 Wakara Way

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(b) On July 21, 2020, Walter Gilbert, Ph.D. announced that he will retire from the Board of Directors (the “Board”) of Myriad Genetics, Inc. (“Myriad”), effective as of the date of Myriad’s 2020 Annual Meeting of Stockholders.

(d)  On July 21, 2020, the Board approved an increase in the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D. Ph.D. to fill the newly created vacancy, effective immediately, to serve as a Class I Director with a term expiring at Myriad’s 2021 Annual Meeting of Stockholders.  The Board has determined that Dr. Skovronsky meets the independence requirements of the Securities and Exchange Commission and the Nasdaq Stock Market Rules.  The Board appointed Dr. Skovronsky to serve on the Research and Product Innovation Committee of the Board, effective immediately.

Dr. Skovronsky will be compensated for his service as director on the same basis as other non-employee directors of Myriad, as more fully described in the “Director Compensation” section of Myriad’s definitive proxy statement for the 2019 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on October 16, 2019.  Pursuant to Myriad’s non-employee director compensation policy, in connection with his appointment to the Board Dr. Skovronsky will be granted a restricted stock unit award for shares of Myriad’s common stock having an aggregate value of $300,000.  The foregoing grant will vest one year following the grant date.  Dr. Skovronsky will also enter into Myriad’s standard indemnification agreement for directors and executive officers.

There are no arrangements or understandings between Dr. Skovronsky and any other person pursuant to which he was selected to serve on the Board, and Dr. Skovronsky is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.

On July 22, 2020, Myriad issued a press release announcing Dr. Skovronsky’s appointment to the Board and Dr. Gilbert’s retirement from the Board, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.

The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.